Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 706-717

  Engram, Jessica C ^a   Dunham, Richard M ^a   Makedonas, George ^a   Vanderford, Thomas H ^a   Sumpter, Beth ^b   Klatt, Nichole R ^a,b   Ratcliffe, Sarah J ^a   Garg, Seema ^b   Paiardini, Mirko ^a   McQuoid, Monica ^b   Altman, John D ^c   Staprans, Silvija I ^a,b,c   Betts, Michael R ^a   Garber, David A ^b   Feinberg, Mark B ^b,c   Silvestri, Guido ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; LENTIVIRUS VECTOR; MODIFIED VACCINIA VIRUS ANKARA; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; EPITOPE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS IMMUNIZATION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; DISEASE COURSE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACACA; MONKEY DISEASE; PATHOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; EPITOPES, T-LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 68949110126     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803746     Document Type: Article

References (51)

1. Garber, D. A., G. Silvestri, and M. B. Feinberg. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4: 397-413.
2. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764.
3. Berkley, S. F., and W. C. Koff. 2007. Scientific and policy challenges to development of an AIDS vaccine. Lancet 370: 94-101.
4. Letvin, N. L. 2007. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 27: 366-369.
5. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
6. + T cells. Blood 107: 4781-4789.
7. Goulder, P. J., and D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. 8: 619-630.
8. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. 4: 630-640.
9. + lymphocytes. Science 283: 857-860.
10. Amara, R. R., K. Patel, G. Niedziela, P. Nigam, S. Sharma, S. I. Staprans, D. C. Montefiori, L. Chenareddi, J. G. Herndon, H. L. Robinson, H. M. McClure, and F. J. Novembre. 2005. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J. Virol. 79: 15356-15367.
11. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
12. Liang, X., D. R. Casimiro, W. A. Schleif, F. Wang, M. E. Davies, Z. Q. Zhang, T. M. Fu, A. C. Finnefrock, L. Handt, M. P. Citron, et al. 2005. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J. Virol. 79: 12321-12331.
13. Ramsburg, E., N. F. Rose, P. A. Marx, M. Mefford, D. F. Nixon, W. J. Moretto, D. Montefiori, P. Earl, B. Moss, and J. K. Rose. 2004. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J. Virol. 78: 3930-3940.
14. Santra, S., Y. Sun, J. G. Parvani, V. Philippon, M. S. Wyand, K. Manson, A. Gomez-Yafal, G. Mazzara, D. Panicali, P. D. Markham, D. C. Montefiori, and N. L. Letvin. 2007. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J. Virol. 81: 8563-8570.
15. Feinberg, M. B., and J. P. Moore. 2002. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8: 207-210.
16. Allen, T. M., P. Jing, B. Calore, H. Horton, D. H. O'Connor, T. Hanke, M. Piekarczyk, R. Ruddersdorf, B. R. Mothe, C. Emerson, et al. 2002. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J. Virol. 76: 10507-10511.
17. Casimiro, D. R., F. Wang, W. A. Schleif, X. Liang, Z. Q. Zhang, T. W. Tobery, M. E. Davies, A. B. McDermott, D. H. O'Connor, A. Fridman, et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79: 15547-15555.
18. Horton, H., T. U. Vogel, D. K. Carter, K. Vielhuber, D. H. Fuller, T. Shipley, J. T. Fuller, K. J. Kunstman, G. Sutter, D. C. Montefiori, et al. 2002. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific Tcell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76: 7187-7202.
19. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312: 1530-1533.
20. Gordon, S. N., N. R. Klatt, S. E. Bosinger, J. M. Brenchley, J. M. Milush, J. C. Engram, R. M. Dunham, M. Paiardini, S. Klucking, A. Danesh, et al. 2007. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 179: 3026-3034.
21. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
22. Allen, T. M., T. U. Vogel, D. H. Fuller, B. R. Mothe, S. Steffen, J. E. Boyson, T. Shipley, J. Fuller, T. Hanke, A. Sette, et al. 2000. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164: 4968-4978.
23. Tritel, M., A. M. Stoddard, B. J. Flynn, P. A. Darrah, C. Y. Wu, U. Wille, J. A. Shah, Y. Huang, L. Xu, M. R. Betts, G. J. Nabel, and R. A. Seder. 2003. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171: 2538-2547. (Pubitemid 37025564)
24. Chattopadhyay, P. K., D. A. Price, T. F. Harper, M. R. Betts, J. Yu, E. Gostick, S. P. Perfetto, P. Goepfert, R. A. Koup, S. C. De Rosa, M. P. Bruchez, and M. Roederer. 2006. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat. Med. 12: 972-977.
25. Silvestri, G., D. L. Sodora, R. A. Koup, M. Paiardini, S. P. O'Neil, H. M. McClure, S. I. Staprans, and M. B. Feinberg. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18: 441-452.
26. Vogel, T. U., M. R. Reynolds, D. H. Fuller, K. Vielhuber, T. Shipley, J. T. Fuller, K. J. Kunstman, G. Sutter, M. L. Marthas, V. Erfle, et al. 2003. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77: 13348-13360.
27. Wilson, N. A., J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, T. Soma, M. R. Reynolds, et al. 2006. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80: 5875-5885.
28. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200: 749-759.
29. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77: 11708-11717.
30. + T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
31. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200: 761-770.
32. + T cell depletion and viral replication in SIV infection. Science 280: 427-431.
33. Brenchley, J. M., D. A. Price, and D. C. Douek. 2006. HIV disease: fallout from a mucosal catastrophe? Nat. Iimmunol. 7: 235-239.
34. Hirsch, V. M., and P. R. Johnson. 1994. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 32: 183-203.
35. Sun, Y., S. Santra, J. E. Schmitz, M. Roederer, and N. L. Letvin. 2008. Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J. Virol. 82: 8812-8819.
36. Leng, Q., G. Borkow, Z. Weisman, M. Stein, A. Kalinkovich, and Z. Bentwich. 2001. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J. AIDS 27: 389-397. (Pubitemid 32729086)
37. Sousa, A. E., J. Carneiro, M. Meier-Schellersheim, Z. Grossman, and R. M. Victorino. 2002. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169: 3400-3406.
38. + T cells is not predictive of simian immunodeficiency virus virulence. J. Immunol. 179: 3035-3046.
39. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407: 386-390.
40. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205: 7-12.
41. Mattapallil, J. J., D. C. Douek, A. Buckler-White, D. Montefiori, N. L. Letvin, G. J. Nabel, and M. Roederer. 2006. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203: 1533-1541.
42. + T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIVmac251 infection. Mucosal Immun. 1: 497-507.
43. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
44. Rodriguez, B., A. K. Sethi, V. K. Cheruvu, W. Mackay, R. J. Bosch, M. Kitahata, S. L. Boswell, W. C. Mathews, D. R. Bangsberg, J. Martin, et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 1498-1506.
45. Broussard, S. R., S. I. Staprans, R. White, E. M. Whitehead, M. B. Feinberg, and J. S. Allan. 2001. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J. Virol. 75: 2262-2275.
46. Rey-Cuille, M. A., J. L. Berthier, M. C. Bomsel-Demontoy, Y. Chaduc, L. Montagnier, A. G. Hovanessian, and L. A. Chakrabarti. 1998. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J. Virol. 72: 3872-3886.
47. Derdeyn, C. A., and G. Silvestri. 2005. Viral and host factors in the pathogenesis of HIV infection. Curr. Opin. Immunol. 17: 366-373.
48. Grossman, Z., M. Meier-Schellersheim, W. E. Paul, and L. J. Picker. 2006. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 12: 289-295.
49. Hurtrel, B., F. Petit, D. Arnoult, M. Muller-Trutwin, G. Silvestri, and J. Estaquier. 2005. Apoptosis in SIV infection. Cell Death Differ. 12(Suppl. 1): 979-990.
50. Vlahakis, S. R., S. A. Bennett, S. N. Whitehead, and A. D. Badley. 2007. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 12: 969-977.
51. Mothe, B. R., J. Weinfurter, C. Wang, W. Rehrauer, N. Wilson, T. M. Allen, D. B. Allison, and D. I. Watkins. 2003. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 77: 2736-2740.